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Objectives:We examined the 4 year trend in antimicrobial susceptibilities and prescribing across levels of care at
two London teaching hospitals and their multisite renal unit, and for the surrounding community.
Methods: Laboratory and pharmacy information management systems were interrogated, with antimicrobial
use and susceptibilities analysed between hospitals, within hospitals and over time.
Results: A total of 108717 isolates from 71687 patients were identified, with significant differences (at P,0.05)
in antimicrobial susceptibility between and within hospitals. Across the 4 years, rates of ESBL-/AmpC-producing
Enterobacteriaceae ranged from 6.4% to 10.7% among community isolates, 17.8% to 26.9% at ward level and
25.2% to 52.5% in critical care. Significant variations were also demonstrated in glycopeptide-resistant entero-
cocci (ward level 6.2%–17.4%; critical care 21.9%–56.3%), MRSA (ward level 18.5%–38.2%; critical care 12.5%–
47.9%) and carbapenem-resistant Pseudomonas spp. (ward level 8.3%–16.9%; critical care 19.9%–53.7%). Few
instances of persistently higher resistance were seen between the hospitals in equivalent cohorts, despite per-
sistently higher antimicrobial use in Hospital 1 than Hospital 2. We found significant fluctuations in non-suscep-
tibility year on year across the cohorts, but with few persistent trends.
Conclusions: The marked heterogeneity of antimicrobial susceptibilities between hospitals, within hospitals and
over time demands detailed, standardized surveillance and appropriate benchmarking to identify possible drivers
and effective interventions. Homogeneous antimicrobial policies are unlikely to continue to be suitable as indi-
vidual hospitals join hospital networks, and policies should be tailored to local resistance rates, at least at the
hospital level, and possibly with finer resolution, particularly for critical care.
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Introduction
Antimicrobial resistance rates vary between countries,1 and
between the community and hospitals.2 Variationwithin hospitals
is also described; internationally, resistance rates are often high-
est in critical care,3,4 but in Europe this varies by organism1 and in
the UK critical care reservoirs seem less apparent.5 Robust bench-
marking is, however, lacking despite advocacy towards the stan-
dardized collection of cumulative antimicrobial susceptibility test
data6 (the ‘antibiogram’).7
The identification of local variations in bacterial resistance
between cohorts2,8 and over time9 enables informed decisions
on empirical antimicrobial regimens and is becoming increasingly
achievable as economic and political pressures create hospital
networks where previously separate units, patient cohorts and
their associated flora are now served by single large centralized
laboratories. However, single antimicrobial policies are frequently
adopted within these networks, often not adequately allowing for
variations in bacterial resistance between and within the sites
served. In this context, antimicrobial policies rarely account for
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the variations in carriage rates of resistant bacteria in relation to
population structure and travel or migration patterns.10 Defining
patient cohorts according to locale, level of care and other
acknowledged risk factors for antimicrobial resistance, with sub-
sequent detailing of resistance trends, may facilitate more appro-
priate antimicrobial prescribing. A further concern is that highly
standardized antimicrobial policies may concentrate selection
pressure on particular agents, sequentially eroding their utility,
exactly as has occurred with anti-gonococcal treatments.11
This study analyses 4 years of bacterial susceptibility data and
prescribing trends from two West London tertiary referral hospi-
tals, their multisite renal unit and the surrounding community
practices, all served by a single laboratory. The objectives were
to identify and describe the fine-resolution variations in resistance
rates and trends between the hospitals andwithin the hospitals at
ward (NHS Level 0 and Level 1 beds) and critical care (NHS Level 2
and Level 3 beds)12 levels, and furthermore to explore the rela-
tionships between resistance patterns and antimicrobial use.
Methods
The laboratory information management system (LIMS; Sunquestw,
Misys) was interrogated for the seven cohorts of interest: Teaching
Hospital 1 (27 critical care beds; 388 ward beds), Teaching Hospital 2 (26
critical care beds; 453 ward beds), the multisite renal unit (84 inpatient
beds and3100 dialysis and transplant outpatients) and community spe-
cimens (from over 50 local primary care practices and from outpatients
attending clinics at Hospitals 1 and 2). Hospital 1 includes general medi-
cine, cardiology and tertiary referral haematology, cardiothoracic surgery
and hepatobiliary surgery. Hospital 2 includes general medicine, general
surgery, trauma and orthopaedics and tertiary referral oncology and
neurosurgery. All patients at Hospital 1, Hospital 2 and the renal unit
were over 16 years of age. A third hospital within the hospital network uti-
lized a different LIMS at the time of this study and was excluded. Infection
advice for all sites is provided by an integrated team of infection specia-
lists, with an established overarching antimicrobial policy and an active
antimicrobial stewardship programme for all hospitals in the network.
Off-policy prescription can occur under the direction of infection
specialists.
All samples submitted for culture for clinical indications (as indicated by
the clinician submitting the sample) were identified covering the four fiscal
years from 2009 to 2013 (in the UK the fiscal year runs from April to March).
They included blood and CSF, respiratory and ear/nose/throat, tissue and
wound, genital and urine samples. Samples submitted for the purposes of
cross-infection screening and MRSA screening were excluded, as variations
in screening practice existed between and within the hospitals. The clinical
criteria and sampling protocols to obtain diagnostic specimens for culture
were uniform across the two hospitals in the correspondingward and critical
care cohorts. Results were de-duplicated for organisms repeatedly isolated
within a 7 day period from the same patient. Laboratory operating proce-
dures followed national standards for microbiological investigation;13 iso-
lates were identified using APIw (bioMe´rieux) from 2009 to 2011 and by
MALDI-TOF spectroscopy (Biotyperw, Bruker) from 2011 to 2013.
Susceptibilities were determined by disc diffusion using BSAC criteria.14
AmpC- and ESBL-producing Enterobacteriaceae were identified by standard
methods.13 Comparisons between sites and cohorts were carried out for
glycopeptide-resistant enterococci (GRE), MRSA, Pseudomonas spp. and
AmpC- and ESBL-producing Enterobacteriaceae (defined as including
Citrobacter spp., Escherichia coli, Enterobacter spp., Hafnia spp., Klebsiella
spp., Morganella spp., Pantoea spp., Proteus spp., Providencia spp.,
Raoultella spp., Serratia spp. and other lactose-fermenting coliforms, but
excluding Salmonella spp. and Shigella spp.). Enterobacteriaceae were con-
sidered at family level rather than for each species separately as standard
operating procedures stipulate identification to genus or species level only
for isolates from specific sample types or with particular resistance patterns.
Non-susceptibility (i.e. resistant and intermediate) proportions were calcu-
lated against the total number of isolates tested in each isolate group.
Antimicrobial usage data were sourced from the hospital network
pharmacy system, and defined daily doses per 1000 occupied bed days
(DDDs/1000 OBDs) were calculated.15 Antimicrobial usage data is based
upon antimicrobials distributed to wards for inpatient and stock supply
and was available to the hospital level for Hospitals 1 and 2 (inpatients
only) and for the renal inpatient practice. All antibacterials were included;
antiviral, antileprotic, antimycobacterial and antihelminthic medications
were excluded. Antimicrobial guidelines were reviewed for the relevant
time periods to identify any policy shifts.
Variable referral practice from local primary care centres precluded an
estimation of population-attributable rates of infection and resistance (i.e.
an extrapolation of the observed rates in the study cohorts out to thewider
population), but isolate frequency was calculated for inpatients based
upon OBDs. CIs for non-susceptibility were calculated using the Wilson
method with continuity correction.16 Analysis was undertaken in Stata/
SE Version 11w, with x2 tests for inter-cohort comparison and for temporal
trends, and with binomial regression analysis when these identified signifi-
cant differences (P,0.05, with the Bonferroni correction to account for
multiple comparisons between years in each cohort).
Results
The LIMS extract yielded antimicrobial susceptibility results for
145703 isolates. After excluding organisms not of interest to
this study, 108717 isolates from 105319 samples and 71687
patients remained.
Isolate frequency in relation to occupancy
denominators
At ward level, little variation was observed between the two hos-
pitals in terms of the frequency of isolation of the species groups
reviewed (Table 1; expressed as isolates/1000 OBDs), with the
exception of an upswing in Enterobacteriaceae isolates in the
most recent year that was observed in both hospitals. The fre-
quency of isolates from the renal inpatient cohort was compar-
able to that from the general ward areas. Marked year-by-year
fluctuations were observed in isolate frequency in critical care
but with a modest overall down-trend. Three features were not-
able: first, the high frequency of isolates of all species groups in
Hospital 1 in critical care in 2009–10, not attributable to any dis-
cernible policy changes, case-mix or known outbreaks; second, a
marked down-trend in the frequency of enterococci in both critical
care units over the study period; and last, a year-on-year decrease
in Enterobacteriaceae isolates from critical care patients at
Hospital 2.
Resistance in Enterobacteriaceae
A total of 55600 Enterobacteriaceae were identified (Table 2).
Significantly higher prevalence rates for Enterobacteriaceae with
ESBL/AmpC phenotypes were seen in critical care versus general
wards in Hospital 1 in three of the four years and in Hospital 2 in
all four years (Table 3 and Figure 1a). The proportions of ESBL/
AmpC phenotypes were 1 in 5 Enterobacteriaceae from general
wards and up to 1 in 2 in critical care. Fluctuating rates of
Enterobacteriaceae with ESBL/AmpC phenotypes were seen at
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the two hospitals, with significant differences in these rates
between the critical care areas in three of the four years, but
only in the two most recent years in general ward cohorts.
ESBL/AmpC rates among Enterobacteriaceae from the renal out-
patient cohort were as high as at hospital ward level and, among
renal inpatients, were as high as in critical care, peaking at 51.5% in
2012–13. The difference in prevalence of ESBL-/AmpC-producing
Enterobacteriaceae between renal inpatients and renal outpatients
was significant in all four years.
Binomial regression demonstrated a significant increase in the
relative proportion of ESBL-/AmpC-producing Enterobacteriaceae
from Hospital 1 ward inpatients from 2009–10 to 2010–11 of
18.8% (95% CI 1.4–39.1%, P¼0.03). Hospital 1 critical care also
showed a significant, 1.8-fold, increase in the prevalence of
these organisms from 2010–11 to 2011–12 (95% CI 1.4–2.3,
P,0.001). In Hospital 2, critical care saw a significant relative
increase in the prevalence of ESBL/AmpC producers from 2009–
10 to 2010–11 of 43.6% (95% CI 20.7–70.9%, P,0.001), fol-
lowed by a relative decrease from 2010–11 to 2011–12 of
23.3% (95% CI 6.3–37.1%, P¼0.009). The proportions of ESBL-/
AmpC-producing Enterobacteriaceae in the community samples
showed significant increases between 2009–10 and 2010–11
(P,0.001) and 2010–11 and 2011–12 (P,0.001) followed by
a dip from 10.7% to 9.5% in 2012–13 (P¼0.03); the year-to-year
variation was, however, small compared with the hospital
cohorts.
Non-susceptibility to ciprofloxacin among the Enterobacteriaceae
varied surprisingly little between orwithin the hospitals (Table 3), with
non-susceptibility rates clustered from 18.1% to 25.7% (Figure 1b).
However, the renal unit showed a significant variation in ciprofloxacin
non-susceptibility between the inpatient and outpatient cohorts in all
four years. For renal outpatients, the prevalence of ciprofloxacin non-
susceptibility was almost double that among ward patients in
Hospitals 1 and 2; that for renal inpatients neared triple those
in Hospitals 1 and 2. There was no significant temporal variation in
ciprofloxacin non-susceptibility in either hospital or in the renal unit.
Non-susceptibility to ciprofloxacin in community isolates was
approximately half that among inpatients.
We saw little carbapenem non-susceptibility in Enterobacteriaceae,
precluding a robust temporal or inter-cohort analysis. Meropenem
non-susceptibility was noted in fewer than 0.5% of all hospital
Enterobacteriaceae, except for isolates from renal inpatients during
2009–10, when an outbreak due to OXA-48-carbapenemase
producing Klebsiella pneumoniaewas detected.17 Ertapenem non-
susceptibility also was noted in 1%–2% of Enterobacteriaceae,
predominantly Enterobacter species, and was attributed to the
breakpoint determining a ‘tail’ of AmpC-derepressed isolates to
be non-susceptible.
Resistance in Pseudomonas
A total of 12616 Pseudomonas spp. were identified, 10226 of
them confirmed as P. aeruginosa (Table 2). Across both hospitals
and the renal cohorts, Pseudomonas spp. comprised 75.3%–
88.9% of all non-fermenters, with 63.0%–77.1% identified as
P. aeruginosa. Non-susceptibility to ciprofloxacin (Figure 2a),
piperacillin/tazobactam (Figure 2b) and meropenem (Figure 2c)
was analysed.
There was a significant variation in ciprofloxacin non-
susceptibility rates between the two hospitals in critical care inTa
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Table 2. Bacterial non-susceptibility to selected antimicrobials among 108717 clinical isolates from primary, secondary and tertiary care patients in West London, 2009–13
Renal Hospital 1 Hospital 2
Community outpatient inpatient wards critical care wards critical care
2009–
10
2010–
11
2011–
12
2012–
13
2009–
10
2010–
11
2011–
12
2012–
13
2009–
10
2010–
11
2011–
12
2012–
13
2009–
10
2010–
11
2011–
12
2012–
13
2009–
10
2010–
11
2011–
12
2012–
13
2009–
10
2010–
11
2011–
12
2012–
13
2009–
10
2010–
11
2011–
12
2012–
13
Enterobacteriaceae
isolates
(55600 total)
13225 12880 5055 6641 314 389 575 703 396 283 293 365 1229 831 965 1661 494 254 248 304 1995 1799 1508 2186 371 289 207 140
ciprofloxacin non-
susceptibility (%)
9.6 11.3 12.0 11.5 36.0 29.6 36.7 42.2 59.1 54.1 54.9 60.8 23.7 26.2 25.7 23.4 24.3 18.1 18.5 23.7 20.1 22.5 20.8 20.7 19.9 25.3 19.8 24.3
AmpC or ESBL
phenotype (%)
6.4 8.2 10.7 9.5 24.5 22.4 27.0 29.9 35.6 38.9 43.3 51.5 21.5 25.5 26.9 21.1 29.1 25.2 44.4 47.0 21.5 23.1 20.8 17.8 36.4 52.2 40.1 36.4
Pseudomonas spp.
isolates
(12616 total)
1869 1954 745 1505 146 133 130 103 155 138 135 102 454 266 213 282 252 111 107 169 820 748 658 652 211 218 207 133
ciprofloxacin non-
susceptibility (%)
12.3 14.3 12.8 11.1 26.7 23.3 15.4 19.4 40.6 45.7 25.9 27.5 25.6 33.8 20.7 22.7 32.5 29.7 34.6 28.4 26.6 20.1 18.4 15.8 35.1 26.6 30.0 39.8
piperacillin/
tazobactam
non-
susceptibility (%)
1.0 2.4 2.3 1.9 2.7 3.8 5.4 2.9 19.4 23.2 3.7 6.9 6.8 12.4 8.0 7.8 8.3 27.0 15.0 13.0 7.7 8.2 5.6 4.4 17.1 17.0 17.4 14.3
meropenem non-
susceptibility (%)
3.6 3.5 5.0 3.2 10.3 6.8 4.6 5.8 32.9 33.3 8.9 18.6 16.7 18.4 10.3 13.1 32.9 39.6 42.1 33.1 15.6 11.6 8.2 8.0 31.8 21.1 27.5 22.6
Enterococci isolates
(13643 total)
2689 3284 1555 1321 77 79 91 102 226 132 93 105 341 281 238 324 188 128 80 89 607 467 370 481 115 100 48 32
amoxicillin non-
susceptibility (%)
1.5 1.0 2.1 2.6 15.6 15.2 8.8 13.7 58.8 56.8 55.9 59.0 43.7 35.6 31.5 34.0 57.4 71.9 61.3 71.9 11.0 21.6 16.5 20.6 67.8 67.0 56.3 43.8
vancomycin non-
susceptibility (%)
0.3 0.4 1.4 1.1 22.1 17.7 14.3 12.8 56.2 59.8 64.5 55.2 17.3 17.4 11.3 15.4 41.5 56.3 25.0 34.8 9.2 9.6 6.2 10.0 55.7 49.0 37.5 21.9
S. aureus isolates
(26858 total)
5076 5495 4382 4658 67 86 111 95 100 79 96 104 402 319 336 517 142 42 52 72 1211 1144 941 932 116 112 96 75
methicillin non-
susceptibility (%)
13.7 12.3 11.3 9.3 16.4 18.6 18.9 14.7 33.0 31.6 24.0 26.9 29.1 38.2 19.9 21.1 19.0 35.7 23.1 12.5 38.3 27.4 25.4 18.5 44.0 39.3 47.9 22.7
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only one year, and at ward level in two years. Within-hospital
comparisons demonstrated significant differences in all four
years in Hospital 2, with the non-susceptibility rate in critical
care almost double that in the general wards (Table 3).
Temporal analysis found no significant variation in ciprofloxacin
non-susceptibility in critical care, but showed significant falls at
ward level in Hospital 2 between 2009–10 and 2010–11
(P¼0.002) and in Hospital 1 between 2010–11 and 2012–13
(P¼0.001). The renal inpatient cohort showed a significant fall
(almost 50%) in ciprofloxacin non-susceptibility between 2010–
11 and 2011–12 (P,0.001). In the community, ciprofloxacin
non-susceptibility among Pseudomonas spp. remained between
11.1% and 14.3% across the four years.
Meropenem non-susceptibility was more prevalent than
piperacillin/tazobactam non-susceptibility in all years and cohorts
(Table 2 and Figure 2b and c). Non-susceptibility to meropenem
was significantly more prevalent (typically 2- to 3-fold) in critical
care than in the general wards in all years at both hospitals
Table 3. Statistical analysis of variation in non-susceptibility between cohorts and over time among 108717 clinical isolates from primary, secondary
and tertiary care patients in West London, 2009–13
Between hospital
critical care:
Hospital 1 versus
Hospital 2
Between hospital
wards: Hospital 1
versus Hospital 2
Within Hospital 1:
critical care
versus wards
Within Hospital 2:
critical care
versus wards
Renal: inpatients
versus
outpatients
Enterobacteriaceae,
ESBL/AmpC phenotype
2009–10 * 2009–10 NS 2009–10 *** 2009–10 *** 2009–10 **
2010–11 *** 2010–11 NS 2010–11 NS 2010–11 *** 2010–11 ***
2011–12 NS 2011–12 *** 2011–12 *** 2011–12 *** 2011–12 ***
2012–13 * 2012–13 ** 2012–13 *** 2012–13 *** 2012–13 ***
Enterobacteriaceae,
ciprofloxacin
non-susceptible
2009–10 NS 2009–10 * 2009–10 NS 2009–10 NS 2009–10 ***
2010–11 * 2010–11 * 2010–11 ** 2010–11 NS 2010–11 ***
2011–12 NS 2011–12 ** 2011–12 * 2011–12 NS 2011–12 ***
2012–13 NS 2012–13 * 2012–13 NS 2012–13 NS 2012–13 ***
Pseudomonas spp.,
ciprofloxacin
non-susceptible
2009–10 NS 2009–10 NS 2009–10 * 2009–10 * 2009–10 *
2010–11 NS 2010–11 *** 2010–11 NS 2010–11 * 2010–11 ***
2011–12 NS 2011–12 NS 2011–12 ** 2011–12 *** 2011–12 *
2012–13 * 2012–13 * 2012–13 NS 2012–13 *** 2012–13 NS
Pseudomonas spp.,
piperacillin/tazobactam
non-susceptible
2009–10 *** 2009–10 NS 2009–10 NS 2009–10 *** 2009–10 ***
2010–11 NS 2010–11 * 2010–11 *** 2010–11 *** 2010–11 ***
2011–12 NS 2011–12 NS 2011–12 NS 2011–12 *** 2011–12 NS
2012–13 NS 2012–13 * 2012–13 NS 2012–13 *** 2012–13 NS
Pseudomonas spp.,
meropenem non-
susceptible
2009–10 NS 2009–10 NS 2009–10 *** 2009–10 *** 2009–10 ***
2010–11 *** 2010–11 ** 2010–11 *** 2010–11 *** 2010–11 ***
2011–12 * 2011–12 NS 2011–12 *** 2011–12 *** 2011–12 NS
2012–13 * 2012–13 * 2012–13 *** 2012–13 *** 2012–13 **
Enterococcus spp.,
glycopeptide
non-susceptible
2009–10 * 2009–10 *** 2009–10 *** 2009–10 *** 2009–10 ***
2010–11 NS 2010–11 ** 2010–11 *** 2010–11 *** 2010–11 ***
2011–12 NS 2011–12 ** 2011–12 ** 2011–12 *** 2011–12 ***
2012–13 NS 2012–13 ** 2012–13 *** 2012–13 * 2012–13 ***
Enterococcus spp.,
amoxicillin
non-susceptible
2009–10 NS 2009–10 *** 2009–10 ** 2009–10 *** 2009–10 ***
2010–11 NS 2010–11 *** 2010–11 ** 2010–11 *** 2010–11 ***
2011–12 NS 2011–12 *** 2011–12 *** 2011–12 *** 2011–12 ***
2012–13 ** 2012–13 *** 2012–13 *** 2012–13 ** 2012–13 ***
S. aureus, methicillin
non-susceptible
2009–10 *** 2009–10 *** 2009–10 * 2009–10 NS 2009–10 *
2010–11 NS 2010–11 *** 2010–11 NS 2010–11 ** 2010–11 *
2011–12 ** 2011–12 * 2011–12 NS 2011–12 *** 2011–12 NS
2012–13 NS 2012–13 NS 2012–13 NS 2012–13 NS 2012–13 *
NS, no significant difference.
*Significant at P,0.05.
**Significant at P,0.01.
***Significant at P,0.001.
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Figure 1. (a) Proportion of Enterobacteriaceae from clinical samples displaying ESBL/AmpC resistance phenotypes among 55600 isolates from primary,
secondary and tertiary care patients in West London, 2009–13. Error bars indicate 95% CIs calculated by Wilson’s method with continuity correction.
(b) Proportion of Enterobacteriaceae from clinical samples resistant to ciprofloxacin among 55600 isolates from primary, secondary and tertiary care
patients in West London, 2009–13. Error bars indicate 95% CIs calculated by Wilson’s method with continuity correction.
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(Table 3). Instances of significant between-hospital variation in
meropenem non-susceptibility were noted between correspond-
ing levels of care, with less variation for piperacillin/tazobactam
non-susceptibility.
There was no statistically significant temporal variation in non-
susceptibility to meropenem or piperacillin/tazobactam in the
ward or critical care cohorts, in renal outpatients or in the commu-
nity. In the renal inpatient cohort, by contrast, there were signifi-
cant falls in the prevalence of non-susceptibility to both
meropenem (33.3% to 8.9%; P,0.001) and piperacillin/tazobac-
tam (23.2% to 3.7%; P,0.001) between 2010–11 and 2011–12.
Resistance in enterococci
A total of 13643 enterococci were identified (Table 2). Significant
differences in GRE rates betweenward and critical care areas were
seen for all years in both hospitals (Table 3 and Figure 3a). A com-
parison between the hospitals demonstrated significant differ-
ences in the prevalence of GRE at ward level in all years but little
significant variation between the critical care areas (with the
exception of 2009–10). GRE were consistently 2–4 times more
frequent among enterococci from renal inpatients than renal out-
patients, and this was significant in all years. There was no signifi-
cant year-on-year variation in the proportion of GRE in any cohort.
An analysis of amoxicillin-non-susceptible enterococci (i.e. pre-
sumptive Enterococcus faecium) demonstrated a significant vari-
ation between critical care and the general ward areas in both
hospitals in all years (Table 3 and Figure 3b); specifically, the propor-
tions of amoxicillin-non-susceptible enterococci in critical carewere
typically twice those in general wards in Hospital 1, and 3–6 times
higher in Hospital 2. A significant variation was also demonstrated
between renal inpatients and outpatients, with the former having
amoxicillin-non-susceptible rates 4 times those for the latter. A
comparison between the two hospitals demonstrated little signifi-
cant variation in the proportion of amoxicillin-non-susceptible
enterococci between the critical care cohorts (with the exception
of 2012–13), but for general ward isolates Hospital 1 consistently
had 1.5–4 times higher rates than Hospital 2. Amoxicillin non-
susceptibility among community isolates was consistent and
10-fold below that of the other cohorts, at 1.0%–2.6%.
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Figure 2. (a) Proportion of Pseudomonas spp. from clinical samples displaying ciprofloxacin non-susceptibility among 12616 isolates from primary,
secondary and tertiary care patients in West London, 2009–13. Error bars indicate 95% CIs calculated by Wilson’s method with continuity
correction. (b) Proportion of Pseudomonas spp. from clinical samples displaying piperacillin/tazobactam non-susceptibility among 12616 isolates
from primary, secondary and tertiary care patients in West London, 2009–13. Error bars indicate 95% CIs calculated by Wilson’s method with
continuity correction. (c) Proportion of Pseudomonas spp. from clinical samples displaying meropenem non-susceptibility among 12616 isolates
from primary, secondary and tertiary care patients in West London, 2009–13. Error bars indicate 95% CIs calculated by Wilson’s method with
continuity correction.
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Figure 2. Continued
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Figure 3. (a) Proportion of enterococci from clinical samples displaying glycopeptide non-susceptibility among 13643 isolates from primary, secondary
and tertiary care patients inWest London, 2009–13. Error bars indicate 95% CIs calculated byWilson’smethodwith continuity correction. (b) Proportion
of enterococci from clinical samples displaying amoxicillin non-susceptibility among 13643 isolates fromprimary, secondary and tertiary care patients in
West London, 2009–13. Error bars indicate 95% CIs calculated by Wilson’s method with continuity correction.
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Resistance in Staphylococcus aureus
A total of 26858 S. aureus isolates were identified, of which 4292
(16.0%) were MRSA (Table 2 and Figure 4). MRSA rates were signifi-
cantly higher in critical care than in the general wards at Hospital 1
only in 2009–10 (Table 3). In Hospital 2, MRSAwasmore prevalent
in critical care areas in two years, with its proportion peaking at
almost twice that at ward level in 2011–12. A comparison
between the hospitals at ward level demonstrated an alternating
trend as to which had the higher MRSA rate; these differences
were significant until 2012–13. In critical care, Hospital 2 had per-
sistently higher MRSA rates than Hospital 1 across all years, and
this was significant in two years. Among renal patients, the pro-
portion of MRSA from the inpatient cohort was significantly higher
than from the outpatient cohort in three of the four years, peaking
at almost double in 2009–10.
An analysis over time showed a significant decrease in the pro-
portion of MRSA at ward level in Hospital 1 between 2010–11 and
2011–12, from 38.2% to 19.9% (P,0.001), with no significant
subsequent rebound. A similar decrease at ward level was
observed in Hospital 2 over a longer period, from 38.2% in
2009–10 to 27.4% in 2010–11 (P,0.001). This was followed by
a further decrease, from 25.4% in 2011–12 to 18.5% in 2012–13
(P,0.001). In critical care, no significant temporal variations were
observed in Hospital 1 but Hospital 2 saw a significant recent
reduction in the proportion of MRSA, from 47.9% in 2011–12 to
22.7% in 2012–13 (P,0.001). In the community, MRSA showed
a downward trend, with significant falls between 2009–10
and 2010–11 (P¼0.02) and between 2011–12 and 2012–
13 (P,0.001).
Antimicrobial usage
Biannual point prevalence studies consistently indicated that
33.3%–41.9% of patients were on antimicrobials, with this pro-
portion rising to 62.9%–71.4% in critical care and to 71.8%–
80.4% among renal inpatients. Analysis as DDDs/1000 OBDs, for
the four most commonly prescribed antimicrobials (ciprofloxacin,
amoxicillin/clavulanate, piperacillin/tazobactam and merope-
nem) among all inpatient groups is shown in Table 4, demonstrat-
ing persistently higher use in Hospital 1 than Hospital 2. This
differential was 23%–56% for ciprofloxacin, 26%–53% for
amoxicillin/clavulanate, 53%–82% for piperacillin/tazobactam,
74%–117% for meropenem and 27%–40% for total antimicro-
bial use. Although the renal unit had a lower use of amoxicillin/cla-
vulanate than either hospital, the use of ciprofloxacin was 159%–
213% higher than for Hospital 2, piperacillin/tazobactam use
104%–147% higher and meropenem use 39%–264% higher.
There was little variation over time in the proportion of prescribing
accounted for by these top four antimicrobials, except for a spike
in meropenem use in Hospital 1 in 2010–11, a reduction by half
for meropenem consumption among renal inpatients between
2010–11 and 2011–12, and for ciprofloxacin, a fall of33% dur-
ing the study period in Hospital 1 and of 20% in the renal inpatient
cohort.
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Figure 4. Proportion of S. aureus from clinical samples displaying methicillin non-susceptibility among 26858 isolates from primary, secondary and
tertiary care patients in West London, 2009–13. Error bars indicate 95% CIs calculated by Wilson’s method with continuity correction.
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A review of antimicrobial policies revealed only two major
changes in the study period, both promoting the use of
narrower-spectrum antimicrobials. The first, in 2010, was the
introduction across the hospital network of an antimicrobial policy
for infection in over-65-year-olds. This stipulated the use of
narrow-spectrum antimicrobials, avoiding amoxicillin/clavulanate
for urinary tract infections, peritonitis and pneumonia (advocating
aminoglycosides, amoxicillin/metronidazole/gentamicin and
amoxicillin, respectively). It aimed to reduce Clostridium difficile
infections. The second major change related to antimicrobial
stewardship in the renal cohort from 2009 onwards (see below).
Discussion
We found significant differences in antimicrobial non-susceptibility
within and between the two hospitals for Enterobacteriaceae,
enterococci, S. aureus and Pseudomonas spp. Furthermore, we
found a substantial year-on-year fluctuation in non-susceptibility
among most ‘drug–bug’ combinations but with few persistent
trends. There was much less fluctuation in results for the commu-
nity cohort, refuting the hypothesis that the variation in the hospital
isolates represented a testing quality issue.
Thedata suggest a few instanceswhere the cohort at onehospital
had persistently higher non-susceptibility rates than the correspond-
ing cohort at the other hospital. Notable examples include MRSA in
Hospital 2 critical care, meropenem-non-susceptible Pseudomonas
spp. in Hospital 1 critical care and amoxicillin-non-susceptible entero-
cocci (i.e. E. faecium) in Hospital 1ward areas. Nevertheless, thewider
lack of consistency in relative rates or trends between the two hos-
pitals suggests that short-term factors were a greater contributor to
influencing the year-on-year variation. These short-term factors
could potentially represent transmission, with many ‘mini-
outbreaks’ among patients who were hospitalized or who had
frequent healthcare contact. A concept of ‘mini-outbreaks’, particu-
larly in the critical care areas, is additionally supported by the fluc-
tuations in the frequency with which species were encountered
within each cohort (Table 1). Further investigation with prospective
large-scale typing is indicated andmay be facilitated by the increas-
ing availability of whole-genome sequencing.
One factor that may contribute to the variation seen between
the two critical care units is the impact of the use of selective
digestive decontamination (SDD)18 in Hospital 2 critical care but
not in Hospital 1. This may help to explain why isolation rates of
Enterobacteriaceae were generally lower in Hospital 2 critical care
than Hospital 1. However, the proportion of Enterobacteriaceae
displaying an ESBL/AmpC phenotype peaked at 52.2% in 2010–
11 at Hospital 2 (twice that in Hospital 1 in the corresponding
year). Over the succeeding 2years, the rates of isolates with
ESBL/AmpC phenotype converged despite there being no change
in SDD practice. Elsewhere, data on the impact of SDD on
multidrug-resistant organisms is conflicting, and long-term
cluster-randomized controlled trials are needed.19,20
In contrast to the general lack of consistency in the differences
in rates of resistance between the two hospitals, the results do
suggest reasonably consistent ‘within-hospital’ variation, with
higher resistance rates and a greater frequency of isolates in crit-
ical care versus ward areas. A consistent excess of resistance was
also seen in the renal cohorts, where resistance rates in renal inpa-
tients resembled those in critical care rather than those found atTa
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ward level; conversely, resistance rates in renal outpatients
resembled those of ward inpatients rather than community
patients. This differential between the proportions of resistant iso-
lates in general versus specialist cohorts was demonstrated for
most ‘drug–bug’ combinations, with the exception of methicillin
resistance for S. aureus and ciprofloxacin non-susceptibility in
Enterobacteriaceae, for which fairly uniform rates were noted
across all cohorts. One of the most likely causes for these ‘within-
hospital’ variations may be the greater frequency of antimicrobial
use in critical care areas/renal inpatients than in general wards. In
our 6-monthly point prevalence studies, antimicrobial usage in
critical care was higher than the benchmarked national point
prevalence finding of 60.8% for critical care patients,21 and
usage in the renal inpatient cohort was higher even than in critical
care. An increased use of devices and central intravenous cannu-
lae in critical care and among renal inpatients may be driving the
frequent empirical co-prescription of glycopeptides, selecting for
GRE.22 Nevertheless, markedly higher antimicrobial prescribing in
Hospital 1 than Hospital 2 was not reflected in higher overall
resistance rates.
Beyond the levels of antimicrobial usage, one of the biggest dri-
vers of variation both between and within hospitals may be the
spectra of activity of the particular antimicrobials prescribed, and
it is widely suggested that resistance itself is encouraging increas-
ingly broad-spectrum empirical antimicrobial use, thereby driving
the selection of further resistance. A possible example was seen
with the spike in meropenem usage in Hospital 1 between 2009–
10 and 2010–11, which was temporally associated with spikes in
piperacillin/tazobactam resistance among Pseudomonas spp. at
both ward and critical care levels. This rise in meropenem use
was associated with a non-significant but possibly consequent
rise in meropenem-non-susceptible Pseudomonas spp. in both
Hospital 1 cohorts, persisting in critical care for the subsequent
year. Addressing this feedback loop through antimicrobial steward-
ship is key, and advances in rapid microbiological diagnostics to
facilitate de-escalation may help.23,24
One example of the successful interruption of such a feedback
loop is demonstrated in the renal cohort data. Until and including
2010–11, meropenem use in this cohort was high. Following an
outbreak of K. pneumoniae with an OXA-48-carbapenemase in
2008–10, carbapenem use was almost halved on the advice of
infection specialists between 2010–11 and 2011–12.While caus-
ality cannot be directly attributed, a beneficial yet unintended
impact over a relatively short time frame was a significant fall in
the proportion of Pseudomonas spp. non-susceptible to merope-
nem. A marked and concordant fall in piperacillin/tazobactam
resistance in Pseudomonas spp.—despite plateaued consumption
in this cohort over this period—may reflect the fact that both
meropenem and piperacillin/tazobactam are affected by, and
putatively select for, the same efflux-based resistance mechan-
isms in P. aeruginosa.
A further facet of antimicrobial use may contribute to the high
burden of antimicrobial non-susceptibility, specifically homoge-
neous use, concentrating the selection pressure on a fraction of
the antimicrobial armamentarium.25,26 In our study, just four
agents consistently represented 34%–50% of all antimicrobials
prescribed in the hospitals and the renal inpatients, and two of
these—amoxicillin/clavulanate and piperacillin/tazobactam—
are closely related. While the damaging consequences of
homogeneous antimicrobial policies are not proven for all
antimicrobials,27 an argument for heterogeneity exists and
might be achieved through antimicrobial cycling28,29 or mix-
ing.30,31 The latter option is likely to be preferable, through offering
broader choices of antimicrobials within policies and prospective
monitoring to preserve the diversity of prescribing within those
choices offered.
Critics of antibiogram-based surveillance data often cite inac-
curacies in the sampling of selected patient populations and
restricted geographical sampling.32 We largely evaded these pro-
blems by extracting all the data from a laboratory servingmultiple
cohorts across two hospitals and an associated community that
shared an overarching antimicrobial policy and infection specia-
lists. Antibiograms can also suffer in accuracy, and therefore util-
ity, when there are marked changes in patient mix. There was
some change in the patient population through this study period,
with solid organ oncology being consolidated from both hospitals
to Hospital 2 in 2010–11, and with the formation of a new heart
attack centre at Hospital 1 in 2009–10. Changes in primary care in
one part of West London between 2010–11 and 2011–12 led to
in a decrease in the number of community samples. Changing
hospital configurations such as these highlight the need for regu-
lar antibiogram review and relation to the patient cohorts. One
limitation of this study is that the susceptibility rates were not
stratified by sample type. When a comparison by sample type
was attempted, meaningful analysis was precluded by low num-
bers. It is acknowledged that rates may potentially vary between
sample types, not least because of sampling bias. However, using
an all-sample approach to resistance surveillance, rather than
restricting data to blood culture results, may better reflect the dri-
vers towards antimicrobial prescribing in clinical practice. A further
limitation is the inability to delineatewhether clinical isolates from
patients in one cohort were acquired in that cohort or elsewhere
(e.g. community-acquired isolates detected during inpatient stays
or hospital-acquired infections becomingmanifest in the commu-
nity). The impact of community antimicrobial use, over and above
hospital use, on the variation in susceptibility rates seen between
cohorts could not be assessed and would require longitudinal,
linked, primary and secondary care patient-level data, not pres-
ently available.
Conclusions
The Annual Report of the Chief Medical Officer,33 the UK Five-Year
Antimicrobial Resistance Strategy,34 the Chennai Declaration35
and the G8 Science Ministers Statement36 all highlight surveillance
as key to addressing antimicrobial resistance. Aggregated regional
or hospital level data are no longer adequate and analysis at a
finer resolution, as here, is needed; however, challenges are posed
by the need to retain sufficient statistical power to detect variation.
A standardization of reporting parameters urgently needs to be
agreed to enable useful surveillance and benchmarking.
Despite (i) overarching antimicrobial and infection control pol-
icies, (ii) standardized laboratory practice and (iii) integrated infec-
tion specialists with an active stewardship programme, this study
found a significant variation in antimicrobial susceptibility in com-
mon organisms between different patient cohorts in the multisite
hospital network. Variations in antimicrobial use and clinical prac-
ticemay be responsible, but relationships are far fromclearand ran-
dom fluctuations, potentially due to numerous ‘mini-outbreaks’,
may be short-term modulators. The marked heterogeneity in
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antimicrobial susceptibility moreover suggests that whole-hospital
antimicrobial policiesmay not be appropriate in hospitals withmul-
tiple sites or where units have markedly different patient popula-
tions. Local policies, rapidly responsive to short-term fluctuations
of both antimicrobial resistance and prescribing patterns, may be
necessary and desirable. Policies should also be mindful of the
potential unintended consequences of reactive prescribing.
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